Los Angeles Capital Management LLC Acquires New Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Los Angeles Capital Management LLC bought a new stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 197,470 shares of the company's stock, valued at approximately $251,000. Los Angeles Capital Management LLC owned approximately 0.16% of Mersana Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in shares of Mersana Therapeutics by 150.5% during the 3rd quarter. State Street Corp now owns 4,059,020 shares of the company's stock worth $27,439,000 after acquiring an additional 2,438,690 shares during the period. Marshall Wace LLP lifted its holdings in shares of Mersana Therapeutics by 377.6% during the 4th quarter. Marshall Wace LLP now owns 2,523,984 shares of the company's stock worth $14,791,000 after acquiring an additional 1,995,516 shares during the period. Braidwell LP lifted its holdings in shares of Mersana Therapeutics by 80.2% during the 1st quarter. Braidwell LP now owns 3,355,805 shares of the company's stock worth $13,792,000 after acquiring an additional 1,493,105 shares during the period. Bank of Montreal Can purchased a new position in shares of Mersana Therapeutics during the 1st quarter worth about $4,665,000. Finally, Boxer Capital LLC purchased a new position in shares of Mersana Therapeutics during the 2nd quarter worth about $3,290,000.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on MRSN. Citigroup upgraded shares of Mersana Therapeutics from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $1.00 to $5.00 in a report on Monday, December 4th. Wedbush reissued a "neutral" rating and set a $2.00 target price on shares of Mersana Therapeutics in a research report on Tuesday, October 31st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $7.17.

Mersana Therapeutics Stock Down 0.6 %

MRSN opened at $3.36 on Monday. The firm has a 50 day moving average price of $2.45 and a 200 day moving average price of $1.79. The company has a market cap of $405.59 million, a PE ratio of -1.89 and a beta of 1.39. Mersana Therapeutics, Inc. has a 1 year low of $0.80 and a 1 year high of $9.62. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.68 and a current ratio of 3.68.

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) last posted its earnings results on Tuesday, November 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.04). Mersana Therapeutics had a negative return on equity of 264.19% and a negative net margin of 482.47%. The business had revenue of $7.70 million for the quarter, compared to analyst estimates of $9.30 million. During the same period last year, the company posted ($0.61) EPS. The firm's revenue for the quarter was up 38.1% compared to the same quarter last year. Sell-side analysts expect that Mersana Therapeutics, Inc. will post -1.49 earnings per share for the current year.

Insider Buying and Selling at Mersana Therapeutics

In other Mersana Therapeutics news, CFO Brian Deschuytner sold 9,327 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $2.71, for a total value of $25,276.17. Following the completion of the sale, the chief financial officer now owns 54,511 shares of the company's stock, valued at $147,724.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Mersana Therapeutics news, CFO Brian Deschuytner sold 9,327 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $2.71, for a total value of $25,276.17. Following the completion of the sale, the chief financial officer now owns 54,511 shares of the company's stock, valued at $147,724.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Anna Protopapas sold 29,399 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $2.71, for a total transaction of $79,671.29. Following the completion of the sale, the director now directly owns 125,153 shares of the company's stock, valued at approximately $339,164.63. The disclosure for this sale can be found here. Insiders sold 47,108 shares of company stock valued at $127,663 over the last 90 days. 12.50% of the stock is owned by corporate insiders.

Mersana Therapeutics Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates.

Want to see what other hedge funds are holding MRSN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.